Tag: Mirocals

The MND Association has published a series of very informative questions and answers in relation to the exciting MND treatment candidate low dose Interleukin 2. You can read them here. Most importantly we await the full publication of the trial results.

On Friday 28th April the MND Association announced something very important for our community – preparation for the potential arrival of effective treatments with regulators, scientists, government and, of course, patients. Patients are working with the MND Association to ensure the fastest possible access to promising treatments, if and when they arrive. This is vital work and very timely.

We are sure many of you will have seen the Mail on Sunday story on Interleukin-2, the treatment under study in the Mirocals trial which has had significant funding from the MND Association and other partners and completed in late 2022. The emerging results, as reported at the 33rd International Symposium on ALS/MND in December…